Dr. Jean Hoffman-Censits on the Future of Atezolizumab in Bladder Cancer

Hoffman-Censits says atezolizumab has recently undergone a phase II clinical trial for patients with bladder cancer who failed platinum-based chemotherapy.

Jean Hoffman-Censits, MD, medical oncologist, director, Multidisciplinary Genitourinary Oncology Center, Thomas Jefferson University Hospital, discusses the potential future of the investigational PD-L1 inhibitor atezolizumab. Hoffman-Censits says atezolizumab has recently undergone a phase II clinical trial for patients with bladder cancer who failed platinum-based chemotherapy.